Published in Hepatitis Weekly, January 2nd, 2006
"It is uncertain if a patient's lamivudine response after HBeAg loss is durable. In Korean chronic hepatitis B patients, the relapse rate is high after termination of lamivudine therapy for patients with HBeAg loss," wrote K.S. Byun and colleagues, Korea University.
"We evaluated the factors related to relapse in chronic hepatitis B patients with HBeAg loss after lamivudine therapy. A total of 132 chronic hepatitis B patients, who initially had HBeAg and did not have decompensated features, were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.